BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and ...

BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for use in patients with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) with HER2 (ERBB2) tyrosine kinase ...

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain ...

This Rx Road Map outlines the most important information nurses should know when treating patients with astrocytoma or oligodendroglioma with vorasidenib.

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...